Stockscreener 앱 받기
18.98
5.53%
-1.145
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge Labs edges down after stock sale hiked to $115 mln - TradingView — Track All Markets
BioAge Labs prices upsized public offering at $19.50 per share By Investing.com - Investing.com Nigeria
Fund Flows: Is BioAge Labs Inc in accumulation or distribution phase2025 Market WrapUp & Reliable Price Action Trade Plans - baoquankhu1.vn
BioAge Labs prices upsized public offering at $19.50 per share - Investing.com
Metabolic disease biotech BioAge raises $115M in stock sale - Stock Titan
BioAge Announces Pricing of Upsized $115.0 Million Public Offering - GlobeNewswire
Dow Update: Will SPDR Gold Trust benefit from rate cutsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Gap DownTime to Sell? - MarketBeat
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
BioAge Announces Proposed $75 Mln Public Offering; Expands BGE-102 Development Into Ophthalmology - Nasdaq
BioAge Labs announces $75 million public stock offering By Investing.com - Investing.com Nigeria
BioAge expands BGE-102 program to diabetic macular edema By Investing.com - Investing.com India
BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating - TipRanks
BioAge stock falls after announcing $75 million public offering By Investing.com - Investing.com UK
BioAge Labs announces $75 million public stock offering - Investing.com
BioAge Announces Proposed Public Offering - manilatimes.net
BioAge Announces Proposed Public Offering - Benzinga
BioAge Labs: Early-Stage NLRP3 Opportunity in Ophthalmology and Cardiometabolic Disease Warrants Neutral ‘Hold’ Amid Long Clinical Timelines - TipRanks
BioAge expanding indication for NLRP3 inhibitor BGE-102 into DME - The Pharma Letter
BioAge expands BGE-102 program to diabetic macular edema - Investing.com
BioAge Labs advances BGE-102 into ophthalmology clinical trials - TipRanks
BioAge Labs, Inc. Expands Indication for BGE-102 to Diabetic Macular Edema - TradingView — Track All Markets
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - The Manila Times
Pill for diabetic eye swelling: BioAge tests oral alternative to eye injections - Stock Titan
BioAge Labs extends rally after updating early-stage trial data for lead drug - MSN
BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
BioAge Labs: Why Getting Into The Brain Might Be A Headache For Investors (NASDAQ:BIOA) - Seeking Alpha
The JPM Effect In Short Supply But BioAge And Bayer Gain - Citeline News & Insights
BioAge Labs (NASDAQ:BIOA) Shares Down 6.1% on Insider Selling - MarketBeat
Bioage Labs Inc (BIOA) Stock Price Down 5.15% on Jan 16 - GuruFocus
Insider Selling: CEO Kristen Fortney Sells Shares of Bioage Labs Inc (BIOA) - GuruFocus
Insider Selling: BioAge Labs (NASDAQ:BIOA) CEO Sells 233,107 Shares of Stock - MarketBeat
Dov Md Goldstein Sells 27,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
Bioage Labs Insider Sold Shares Worth $4,223,036, According to a Recent SEC Filing - marketscreener.com
Bioage Labs Insider Sold Shares Worth $531,828, According to a Recent SEC Filing - marketscreener.com
BioAge Labs (NASDAQ:BIOA) Shares Up 7.1%Time to Buy? - MarketBeat
BioAge reports 86% reduction in inflammation markers with BGE-102 By Investing.com - Investing.com India
BioAge Labs (NASDAQ:BIOA) Reaches New 1-Year HighShould You Buy? - MarketBeat
BioAge stock soars 21% on positive data for inflammation drug By Investing.com - Investing.com South Africa
BioAge stock soars 21% on positive data for inflammation drug - Investing.com
BioAge Labs advances BGE-102 with strong Phase 1 data - TipRanks
BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView — Track All Markets
BioAge announces additional positive interim phase 1 data for BGE-102, a novel brain-penetrant NLRP3 inhibitor, demonstrating potential for best-in-class hsCRP reduction in participants with elevated cardiovascular risk - marketscreener.com
Experimental pill sharply cuts heart inflammation in 2 weeks - Stock Titan
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with... - markets.businessinsider.com
Institutional investors are BioAge Labs, Inc.'s (NASDAQ:BIOA) biggest bettors and were rewarded after last week's US$51m market cap gain - simplywall.st
Weekly Earnings: Will The Chemours Company 2CU stock benefit from sector leadershipWeekly Trading Summary & Safe Capital Growth Plans - Bộ Nội Vụ
Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Reactions & Fast Exit Strategy with Risk Control - ulpravda.ru
Can BioAge Labs Inc. stock deliver sustainable ROERelative Strength Index (RSI) & Individual Stock Tracking Service - bollywoodhelpline.com
Aug Ideas: Will BioAge Labs Inc. stock maintain growth storyRate Hike & Target Return Focused Stock Picks - Улправда
How analysts rate BioAge Labs Inc. stock todayJuly 2025 News Drivers & Reliable Momentum Entry Alerts - Улправда
Is BioAge Labs Inc. (Y7G) stock included in top ETFs2025 Pullback Review & Low Drawdown Momentum Trade Ideas - ulpravda.ru
What MACD trends signal for BioAge Labs Inc. (Y7G) stockQuarterly Risk Review & Verified Swing Trading Watchlist - Улправда
Why BioAge Labs Inc. stock could outperform in 20252025 Volume Leaders & Reliable Volume Spike Trade Alerts - Улправда
3.13%
자본화:
|
볼륨(24시간):